738567-61-8Relevant articles and documents
Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: Optimization from lipid profiles
Brown, George R.,Hollinshead, David M.,Stokes, Elaine S. E.,Clarke, David S.,Eakin, M. Allan,Foubister, Alan J.,Glossop, Steven C.,Griffiths, David,Johnson, Michael C.,McTaggart, Fergus,Mirrlees, Donald J.,Smith, Graham J.,Wood, Robin
, p. 1306 - 1311 (1999)
Novel 3-substituted quinuclidine inhibitors of cholesterol biosynthesis are reported. Compounds were optimized against oxidosqualene cyclase- lanosterol synthase (OSC) inhibition in vivo, rather than by the conventional optimization of structure-activity
3-Quinuclidinyl heteroatom bridged biaryl derivatives
-
Page/Page column 27, (2010/02/12)
Compounds of formula (I) or a pharmaceutically acceptable salt, amide, or prodrug thereof, wherein: n is 0, 1, or 2; X1 is O, S, —N(R1)—, —N(Ar2)—, and N(R2)C(O)—; Ar1 is a six-membered aromatic ring; Ar2 is cyclohexyl or a mono- or bicyclic aromatic ring, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
